In this Phase II trial conducted by the Dana–Farber Cancer Institute, women aged 50–75 with T1N0, ER-HER2- breast cancer treated with breast-conserving surgery and receiving endocrine therapy with a low PAM-50 score are given the option to omit radiation. This evidence concerns the gene ERBB2 and breast carcinoma.